

- cont*
02
23. (new) A hard gelatin capsule of claim 21 wherein the cyclosporin is Cyclosporin A.
24. (new) A hard gelatin capsule of claim 21 wherein the polyethoxylated saturated hydroxy-fatty acid comprises polyethylene glycol-660-12-hydroxy-stearate.
25. (new) A hard gelatin capsule of claim 21 wherein the C₂-C₃ alcohol comprises ethanol, propylene glycol, or ethanol and propylene glycol.
26. (new) A hard gelatin capsule of claim 25 wherein the C₂-C₃ alcohol comprises ethanol.
27. (new) A hard gelatin capsule of claim 21 wherein the cyclosporin is present in an amount of between 1 to 20 wt-% based on the weight of the composition.
28. (new) A hard gelatin capsule of claim 21 wherein the polyethoxylated saturated hydroxy-fatty acid is present in an amount of between 15 to 95 wt-% based on the weight of the composition.
29. (new) A hard gelatin capsule of claim 21 wherein the C₂-C₃ alcohol is present in an amount of up to 40 wt-% based on the weight of the composition.
30. (new) A hard gelatin capsule of claim 21 wherein components (a), (b), and (c) are present in the ratio 1 to 4 parts (a) : 6 to 15 parts (b) : 3 to 12 parts (c), all parts by weight.
31. (new) A method of treating or preventing organ or tissue transplant rejection which comprises administering to a patient in need thereof a hard gelatin capsule of claim 21.
32. (new) A method which comprises orally administering a capsule of claim 21 to a patient in need thereof.
33. (new) A hard gelatin capsule of claim 21 further comprising
(d) mono-, di- and/or triesters of fatty acids, and optionally
(e) ricinoleic acid glyceride(s) together with smaller proportions of multiply unsaturated fatty acid glycerides or castor oil
as a unit dosage form.